Monday, February 6, 2023
Google search engine
HomeMarketResultsbluebird bio (NASDAQ:BLUE) Price Target Increased to $9.00 by Analysts at SVB...

bluebird bio (NASDAQ:BLUE) Price Target Increased to $9.00 by Analysts at SVB Leerink


bluebird bio (NASDAQ:BLUEGet Rating) had its goal worth elevated by funding analysts at SVB Leerink from $8.00 to $9.00 in a analysis notice issued on Friday, Benzinga stories. The brokerage presently has a “market carry out” score on the biotechnology firm’s inventory. SVB Leerink’s worth goal factors to a possible upside of 12.92% from the corporate’s present worth.

A number of different equities analysis analysts have additionally commented on BLUE. StockNews.com initiated protection on bluebird bio in a analysis notice on Wednesday, October twelfth. They set a “promote” score for the corporate. Royal Financial institution of Canada dropped their worth goal on bluebird bio to $8.00 and set a “sector carry out” score for the corporate in a analysis report on Tuesday, November eighth. Lastly, Raymond James elevated their worth goal on bluebird bio from $8.00 to $10.00 and gave the inventory an “outperform” score in a analysis report on Tuesday, September twentieth. Three analysts have rated the inventory with a promote score, six have issued a maintain score and one has assigned a purchase score to the corporate. In line with knowledge from MarketBeat, the corporate has a median score of “Maintain” and a consensus goal worth of $6.75.

bluebird bio Worth Efficiency

NASDAQ BLUE traded up $0.09 throughout buying and selling hours on Friday, reaching $7.97. The corporate’s inventory had a buying and selling quantity of 51,103 shares, in comparison with its common quantity of two,704,801. The agency has a market capitalization of $660.79 million, a price-to-earnings ratio of -1.29 and a beta of 0.99. bluebird bio has a 1-year low of $2.87 and a 1-year excessive of $10.15. The corporate’s 50-day transferring common is $7.29 and its two-hundred day transferring common is $6.24.

bluebird bio (NASDAQ:BLUEGet Rating) final launched its quarterly earnings outcomes on Monday, November seventh. The biotechnology firm reported ($0.92) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.28) by $0.36. The corporate had income of $0.07 million throughout the quarter, in comparison with analysts’ expectations of $2.25 million. bluebird bio had a unfavourable return on fairness of 173.58% and a unfavourable web margin of 8,828.28%. Equities analysts forecast that bluebird bio will put up -4.18 EPS for the present fiscal yr.

Institutional Inflows and Outflows

Massive buyers have not too long ago added to or diminished their stakes within the firm. Caxton Associates LP lifted its stake in bluebird bio by 559.6% throughout the second quarter. Caxton Associates LP now owns 220,154 shares of the biotechnology firm’s inventory value $911,000 after buying an extra 186,778 shares within the final quarter. Virtu Monetary LLC acquired a brand new stake in shares of bluebird bio within the second quarter valued at $291,000. Monaco Asset Administration SAM acquired a brand new stake in shares of bluebird bio within the second quarter valued at $1,267,000. WINTON GROUP Ltd acquired a brand new stake in shares of bluebird bio within the second quarter valued at $128,000. Lastly, Walleye Capital LLC raised its stake in shares of bluebird bio by 1,185.6% within the first quarter. Walleye Capital LLC now owns 129,729 shares of the biotechnology firm’s inventory valued at $629,000 after buying an extra 119,638 shares within the final quarter. 79.01% of the inventory is presently owned by institutional buyers and hedge funds.

bluebird bio Firm Profile

(Get Rating)

bluebird bio, Inc, a biotechnology firm, researches, develops, and commercializes transformative gene therapies for extreme genetic ailments. Its product candidates for extreme genetic ailments embody betibeglogene autotemcel for the remedy of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the remedy of sickle cell illness (SCD); and elivaldogene autotemcel to deal with cerebral adrenoleukodystrophy.

Additional Studying

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

This immediate information alert was generated by narrative science expertise and monetary knowledge from MarketBeat to be able to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial crew previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.

Earlier than you take into account bluebird bio, you will need to hear this.

MarketBeat retains observe of Wall Road’s top-rated and greatest performing analysis analysts and the shares they suggest to their purchasers every day. MarketBeat has recognized the five stocks that prime analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and bluebird bio wasn’t on the checklist.

Whereas bluebird bio presently has a “Maintain” score amongst analysts, top-rated analysts imagine these 5 shares are higher buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover



Source link

RELATED ARTICLES
- Advertisment -
Google search engine

Most Popular

Recent Comments